Rna for Inhibiting Sars-Cov-2 Replication

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes specific double-stranded RNA molecules (including siRNA and shRNA) designed to inhibit the replication of SARS-CoV-2, the virus responsible for COVID-19. These RNAs target a highly conserved sequence at the 5'-untranslated region (5'-UTR) of the viral genome, making them effective at blocking viral RNA synthesis in infected cells. The invention also proposes pharmaceutical preparations, including inhalation formulations and methods for delivering these RNA molecules, as treatments for diseases caused by coronaviruses.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of COVID-19 in humans, especially in patients with severe or persistent infection.
• Preventive therapy for high-risk populations or healthcare workers who are exposed to coronaviruses.
• Treatment for other diseases caused by related coronaviruses (e.g., SARS-CoV-1), given the highly conserved RNA target region.
• Development of inhalation-based antiviral therapies to directly target respiratory infections.
• Laboratory and research applications for studying viral replication and screening antiviral agents.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets a highly conserved sequence in the coronavirus genome, reducing the risk of viral escape mutations and making therapies broadly applicable across different variants and related viruses.
• Demonstrated high efficacy in inhibiting viral replication in vitro, including against variants like SARS-CoV-2 alpha and SARS-CoV-1.
• Potential for administration by inhalation, enabling direct delivery to the lungs—the primary site of COVID-19 infection—which may improve therapeutic effectiveness and reduce systemic side effects.
• Pharmaceutical preparations can include combinations of siRNAs or shRNAs to further minimize viral escape and increase therapeutic efficacy.
• The approach leverages RNA interference (RNAi), a proven method for specific post-transcriptional gene silencing, offering targeted antiviral therapy with potentially good safety profiles.
• Adaptable delivery methods, including use of adeno-associated virus vectors, broaden potential clinical applications and patient accessibility.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to an RNA for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. According to an aspect of the invention, the RNA is an at least partially double-stranded RNA having a sequence being at least 95 % identical to a sequence chosen from the group consisting of SEQ ID NO. 6 and SEQ ID NO. 11.